Fluticasone propionate/salmeterol (Advair Diskus) vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair Diskus)
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)
Result source: NCT00920959
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone propionate/salmeterol (Advair Diskus) | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| Severe exacerbations, annualised rate | 2.6 vs 2.7vs FP DISKUSNCT00452348 | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 |
| Trough FEV1, change | 0.1 vs 0.1vs FF/VINCT029246885 other results
| —Not posted · NCT00646620 |
| ACQ-5, change | —Not posted · NCT00920959 | —Not posted · NCT00646620 |
| OCS dose reduction | —Not posted · NCT00920959 | —Not posted · NCT00646620 |
Severe exacerbations, annualised rate
- Fluticasone propionate/salmeterol (Advair Diskus)
- 2.6 vs 2.7vs FP DISKUSNCT00452348
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
Trough FEV1, change
- Fluticasone propionate/salmeterol (Advair Diskus)
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs -0.1 NCT00557440
- 0.2 vs 0.1 NCT00452348
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
ACQ-5, change
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
OCS dose reduction
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Fluticasone propionate/salmeterol (Advair Diskus): 6 of 6 rows · Fluticasone propionate/salmeterol (Advair HFA): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair Diskus) Rows use multiple source trials | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| Asthma Symptom Free absolute value · % of time | 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BIDa,b,c NCT00118716 · Phase 4 · registry result, not featured evidence | 37.1 vs 28.5 Fluticasone Propionate % of time @ 52wk250/50 mcg BIDa,b,c NCT00452699 · Phase 4 · registry result, not featured evidence |
| FEV1 absolute change · L | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailyd,e,a,b,f NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence | 0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDe,a,b,f NCT00452699 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 0.2%g NCT01475721 · Phase 4 show 14 more results25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 7.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | —50/100 mcg/dayh NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT01475721 · Phase 4 show 14 more results1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 0.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | —50/100 mcg/dayh NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 2.3%g NCT01475721 · Phase 4 show 14 more results2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 4.4%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0%100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence 0% NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | 0%50/100 mcg/dayh NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 14 more results250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/31.25/25 mcg nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 250/50 mcg BID headache 11% hypertension 6.1% blood pressure increased 0% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 250/50 mcg BID headache 12.2% hypertension 4.9% blood pressure increased 3.7% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100mcg/50mcg cough 5% upper respiratory infection 5% viral upper respiratory infection 5% NCT00927758 · Phase 2 · registry result, not featured evidence headache 5.6% (placebo 5.4%) NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | 50/100 mcg/dayh upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 4 weeks versus 52 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 3 versus Phase 4.
- fAssessment timepoints differ: 24 weeks versus 52 weeks.
- gPopulation comparability has not been reviewed for 8 of these studies.
- hPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair Diskus)
show 5 more results
show 2 more results
+ 20 further endpoints in the CSV export.
Fluticasone propionate/salmeterol (Advair HFA)
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair Diskus)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape